Formulating Relief for RA & ITP

PRTX-100 is positioned to address a major unmet need in the autoimmune sector with Rheumatoid Arthritis (RA) and Immune Thrombocytopenia (ITP)

Learn More

About Protalex

Protalex is a biotechnology company developing a new class of drugs with the potential to revolutionize the treatment of autoimmune diseases.

Autoimmune Diseases

Today in the US, millions of individuals suffer from autoimmune diseases with Rheumatoid Arthritis and Immune Thrombocytopenia representing both large and niche markets.

Leadership Team

Protalex has an Experienced Management with committed support from an expert Scientific Advisory Board

Product Pipeline
Protalex, Inc. Pipeline

* European-based PRTX-100-203 to begin Q3 2015

Investor Presentation

View our latest Corporate Presentation

Download
Sign Up for Email Alerts Be the first to receive breaking news Sign Up